keyword
MENU ▼
Read by QxMD icon Read
search

ramelteon

keyword
https://www.readbyqxmd.com/read/29595562/effect-of-administration-of-ramelteon-a-melatonin-receptor-agonist-on-the-duration-of-stay-in-the-icu-a-single-center-randomized-placebo-controlled-trial
#1
Mitsuaki Nishikimi, Atsushi Numaguchi, Kunihiko Takahashi, Yasuhiro Miyagawa, Kota Matsui, Michiko Higashi, Go Makishi, Shigeyuki Matsui, Naoyuki Matsuda
OBJECTIVES: Occurrence of delirium in the ICU is associated with a longer stay in the ICU. To examine whether the use of ramelteon, a melatonin agonist, can prevent delirium and shorten the duration of ICU stay of critically ill patients. DESIGN: A single-center, triple-blinded, randomized placebo-controlled trial. SETTING: ICU of an academic hospital. PATIENTS: Eligible patients were ICU patients who could take medicines orally or through a nasogastric tube during the first 48 hours of admission...
March 27, 2018: Critical Care Medicine
https://www.readbyqxmd.com/read/29542814/effects-of-ramelteon-on-cardiac-injury-and-adipose-tissue-pathology-in-rats-with-metabolic-syndrome
#2
Ayako Uchinaka, Yuri Kawashima, Yuki Sano, Shogo Ito, Yusuke Sano, Kai Nagasawa, Natsumi Matsuura, Mamoru Yoneda, Yuichiro Yamada, Toyoaki Murohara, Kohzo Nagata
Melatonin regulates circadian rhythms but also has antioxidative and anti-inflammatory effects that ameliorate metabolic disorders. We investigated the effects of the selective melatonin agonist ramelteon on cardiac and adipose tissue pathology in the DahlS.Z-Leprfa /Leprfa (DS/obese) rat, a model of metabolic syndrome (MetS). Rats were treated with a low (0.3 mg/kg per day) or high (8 mg/kg per day) dose of ramelteon from 9 to 13 weeks of age. Ramelteon treatment at either dose attenuated body weight gain, left ventricular fibrosis, and diastolic dysfunction, as well as cardiac oxidative stress and inflammation, without affecting hypertension or insulin resistance...
March 15, 2018: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/29487083/drugs-for-insomnia-beyond-benzodiazepines-pharmacology-clinical-applications-and-discovery
#3
REVIEW
Tobias Atkin, Stefano Comai, Gabriella Gobbi
Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have many side effects, including cognitive impairment, tolerance, rebound insomnia upon discontinuation, car accidents/falls, abuse, and dependence liability. Consequently, the clinical use of off-label drugs and novel drugs that do not target the GABAergic system is increasing. The purpose of this review is to analyze the neurobiological and clinical evidence of pharmacological treatments of insomnia, excluding the BZDs and Z-drugs...
April 2018: Pharmacological Reviews
https://www.readbyqxmd.com/read/29470590/correction-to-chronomedicine-and-type-2-diabetes-shining-some-light-on-melatonin
#4
Andrew C Forrestel, Susanne U Miedlich, Michael Yurcheshen, Steven D Wittlin, Michael T Sellix
The authors have been made aware that the following sentence is incorrect: 'Like IIK7, both ramelteon and tasimelteon have a greater affinity for the MT2 receptor [162].'
February 22, 2018: Diabetologia
https://www.readbyqxmd.com/read/29397559/anti-oxidative-effects-of-melatonin-receptor-agonist-and-omega-3-polyunsaturated-fatty-acids-in-neuronal-sh-sy5y-cells-deciphering-synergic-effects-on-anti-depressant-mechanisms
#5
Senthil Kumaran Satyanarayanan, Yin-Hwa Shih, Yu-Chuan Chien, Shih-Yi Huang, Piotr Gałecki, Siegfried Kasper, Jane Pei-Chen Chang, Kuan-Pin Su
Omega-3 polyunsaturated fatty acids (n-3 or omega-3 PUFAs) and melatonin receptor agonist ramelteon (RMT) both display antidepressant effects, while their cellular effects on anti-oxidative and neuroprotective mechanisms might be different. In this study, we aimed to decipher the individual and synergistic actions of n-3 PUFAs and RMT, as compared with the conventional antidepressant fluoxetine (FLX), in a cellular model of oxidative stress, which might play an important role in the pathophysiology of depression and associated disorders...
February 3, 2018: Molecular Neurobiology
https://www.readbyqxmd.com/read/29381514/activation-of-melatonin-receptors-by-ramelteon-induces-cardioprotection-by-postconditioning-in-the-rat-heart
#6
Martin Stroethoff, Friederike Behmenburg, Kerstin Spittler, Annika Raupach, André Heinen, Markus W Hollmann, Ragnar Huhn, Alexander Mathes
Activation of melatonin receptors protects the heart against ischemia-reperfusion injury. Ramelteon, a clinically used drug for insomnia, acts via activation of melatonin receptors. We investigated whether ramelteon induces acute infarct size reduction by postconditioning. Male Wistar rats were randomized to 6 groups. Hearts were treated with melatonin and ramelteon at the beginning of reperfusion. The melatonin receptor inhibitor luzindole was administered with and without melatonin and ramelteon, respectively...
January 29, 2018: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/29365800/ramelteon-reduces-serum-ldl-and-non-hdl-cholesterol-levels-in-patients-with-insomnia
#7
Noriaki Kume, Haruki Torii, Rumiko Shimizu, Daisuke Yasuda, Yoshinori Hiraoka, Tohru Hashida
No abstract text is available yet for this article.
August 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28993551/usefulness-of-two-compartment-model-assisted-and-static-overall-inhibitory-activity-method-for-prediction-of-drug-drug-interaction
#8
Katsumi Iga, Akiko Kiriyama
Our study of drug-drug interaction (DDI) started with the clarification of unusually large DDI observed between ramelteon (RAM) and fluvoxamine (FLV). The main cause of this DDI was shown to be the extremely small hepatic availability of RAM (vFh ). Traditional DDI prediction assuming the well-stirred hepatic extraction kinetic ignores the relative increase of vFh by DDI, while we could solve this problem by use of the tube model. Ultimately, we completed a simple and useful method for prediction of DDI. Currently, DDI prediction becomes more complex and difficult when examining issues such as dynamic changes in perpetrator level, inhibitory metabolites, etc...
December 1, 2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28992822/therapy-update-for-insomnia-in-the-elderly
#9
REVIEW
Sum Lam, Lucy O Macina
OBJECTIVE: To offer an update on insomnia in older adults and treatment options. DATA SOURCES: A search of PubMed using the terms "insomnia" and "older adults" was performed. Current guidelines, review articles, and drug database and manufacturer package inserts were utilized to provide relevant information. STUDY SELECTION: All English-language articles from 2012 to February 2017 and their bibliographies were reviewed for relevance...
October 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28933013/role-of-ramelteon-in-reduction-of-as-needed-antipsychotics-in-elderly-patients-with-delirium-in-a-general-hospital-setting
#10
Aaron Pinkhasov, Sara A James, Melissa Fazzari, Deepan Singh, Sum Lam
BACKGROUND AND OBJECTIVE: Abnormalities in melatonin levels have been linked to delirium. This dysregulation may be offset with the use of ramelteon, a melatonin receptor agonist. The purpose of this study was to evaluate the role of ramelteon in decreasing the need for as-needed (PRN) use of antipsychotics in elderly patients with delirium. METHODS: This was a single-center, retrospective study involving 488 patients who were placed on constant observation and received care by psychiatric service from May 2015 through October 2015...
December 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28725169/postoperative-delirium-after-pharyngolaryngectomy-with-esophagectomy-a-role-for-ramelteon-and-suvorexant
#11
Eisuke Booka, Yasuhiro Tsubosa, Teruaki Matsumoto, Mari Takeuchi, Takashi Kitani, Masato Nagaoka, Atsushi Imai, Tomoyuki Kamijo, Yoshiyuki Iida, Ayako Shimada, Katsushi Takebayashi, Masahiro Niihara, Keita Mori, Tetsuro Onitsuka, Hiroya Takeuchi, Yuko Kitagawa
BACKGROUND: Postoperative delirium is common after extensive surgery, and is known to be associated with sleeping medications. In this study, we aimed to investigate the relationships between sleeping medications and postoperative delirium after pharyngolaryngectomy with esophagectomy. METHODS: We performed a retrospective analysis of 65 patients who underwent pharyngolaryngectomy with esophagectomy at Shizuoka Cancer Center Hospital between January 2012 and March 2016...
2017: Esophagus: Official Journal of the Japan Esophageal Society
https://www.readbyqxmd.com/read/28662460/efficacy-and-safety-of-sublingual-ramelteon-as-an-adjunctive-therapy-in-the-maintenance-treatment-of-bipolar-i-disorder-in-adults-a-phase-3-randomized-controlled-trial
#12
Atul R Mahableshwarkar, Joseph R Calabrese, Thomas A Macek, Kumar Budur, Adedeji Adefuye, Xinxin Dong, Elizabeth Hanson, Gary S Sachs
BACKGROUND: The optimal long-term management strategy for bipolar I disorder patients is not yet established. Evidence supports the rationale for circadian rhythm regulation to prevent mood episode relapse in bipolar patients. This study evaluated the efficacy and safety of a new sublingual formulation of the melatonin receptor agonist ramelteon (ramelteon SL) as adjunctive therapy in the maintenance treatment of bipolar I patients. METHODS: In a double-blinded trial in the United States and Latin America, adult bipolar I disorder patients stable for ≥ 8 weeks before baseline and with a mood episode 8 weeks to 9 months before screening, were randomized to once-daily ramelteon SL 0...
October 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28627372/regulatory-role-of-melatonin-and-bmp-4-in-prolactin-production-by-rat-pituitary-lactotrope-gh3-cells
#13
Kanako Ogura-Ochi, Satoshi Fujisawa, Nahoko Iwata, Motoshi Komatsubara, Yuki Nishiyama, Naoko Tsukamoto-Yamauchi, Kenichi Inagaki, Jun Wada, Fumio Otsuka
The effects of melatonin on prolactin production and its regulatory mechanism remain uncertain. We investigated the regulatory role of melatonin in prolactin production using rat pituitary lactotrope GH3 cells by focusing on the bone morphogenetic protein (BMP) system. Melatonin receptor activation, induced by melatonin and its receptor agonist ramelteon, significantly suppressed basal and forskolin-induced prolactin secretion and prolactin mRNA expression in GH3 cells. The melatonin MT2 receptor was predominantly expressed in GH3 cells, and the inhibitory effects of melatonin on prolactin production were reversed by treatment with the receptor antagonist luzindole, suggesting functional involvement of MT2 action in the suppression of prolactin release...
June 13, 2017: Peptides
https://www.readbyqxmd.com/read/28579782/effect-of-aripiprazole-on-non-24-hour-sleep-wake-rhythm-disorder-comorbid-with-major-depressive-disorder-a-case-report
#14
Kentaro Matsui, Yoshikazu Takaesu, Takeshi Inoue, Ken Inada, Katsuji Nishimura
BACKGROUND: Patients with non-24-hour sleep-wake rhythm disorder (N24SWD) exhibit a sleep pattern that is asynchronous with the external light-dark cycle, typically involving a cycling, relapsing-remitting pattern of sleep disturbances, including nighttime insomnia and daytime sleepiness. Here, we report the case of a patient with N24SWD comorbid with major depressive disorder, who was successfully treated with a low dose of aripiprazole. CASE PRESENTATION: A 47-year-old female presented with an 8-year complaint of difficulty falling asleep and waking up in the morning...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28516430/ramelteon-improves-post-traumatic-stress-disorder-like-behaviors-exhibited-by-fatty-acid-binding-protein-3-null-mice
#15
Yasushi Yabuki, Ibuki Takahata, Kazuya Matsuo, Yuji Owada, Kohji Fukunaga
We previously reported that fatty acid-binding protein 3 (FABP3) knockout (Fabp3 (-/-)) mice exhibit abnormal dopamine-related behaviors such as enhanced dopamine D2 receptor antagonist-induced catalepsy behaviors. Here, we report that Fabp3 null mice exhibit cognitive deficits, hyperlocomotion and impaired fear extinction, and thus show post-traumatic stress disorder (PTSD)-like behaviors. Notably, chronic administration of ramelteon (1.0 mg/kg, p.o.), a melatonin receptor agonist, improved all PTSD-like behaviors tested in Fabp3 (-/-) mice...
May 17, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28508438/the-effect-of-chronotherapy-on-delirium-in-critical-care-a-systematic-review
#16
Roseanne Luther, Anne McLeod
BACKGROUND: Delirium is highly prevalent within critical care and is linked to adverse clinical outcomes, increased mortality and impaired quality of life. Development of delirium is thought to be caused by multiple risk factors, including disruption of the circadian rhythm. Chronotherapeutic interventions, such as light therapy, music and use of eye shades, have been suggested as an option to improve circadian rhythm within intensive care units. AIM: This review aims to answer the question: Can chronotherapy reduce the prevalence of delirium in adult patients in critical care? DESIGN: This study is a systematic review of quantitative studies...
May 15, 2017: Nursing in Critical Care
https://www.readbyqxmd.com/read/28382516/ramelteon-a-selective-mt1-mt2-receptor-agonist-suppresses-the-proliferation-and-invasiveness-of-endometrial-cancer-cells
#17
Kiyono Osanai, Yoichi Kobayashi, Masahiro Otsu, Tomoko Izawa, Keiji Sakai, Mitsutoshi Iwashita
The incidence of endometrial cancer is increasing, making it the fifth most common cancer worldwide. To date, however, there is no standard therapy for patients with recurrent endometrial cancer. Melatonin, a hormone secreted by the pineal gland, has been shown to have anti-tumor effects in various tumor types. Although melatonin is available as a supplement, it has not been approved for cancer treatment. Ramelteon, a selective melatonin receptor type 1 and 2 (MT1/MT2) receptor agonist, has been approved to treat sleep disorders, suggesting that ramelteon may be effective in the treatment of endometrial cancer...
July 2017: Human Cell
https://www.readbyqxmd.com/read/28270270/a-review-of-suvorexant-doxepin-ramelteon-and-tasimelteon-for-the-treatment-of-insomnia-in-geriatric-patients
#18
REVIEW
Chelsey Edmonds, Michael Swanoski
Geriatric patients often experience insomnia because of physiological and neurological changes that occur during the aging process. Use of benzodiazepines, nonbenzodiazepine hypnotics, and diphenhydramine for the treatment of insomnia pose an increased risk of cognitive impairment, falls, and fractures in this patient population. Therapeutic alternatives approved by the Food and Drug Administration include suvorexant, doxepin, ramelteon, and tasimelteon, which have shown efficacy and safety in various studies...
March 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28075519/an-update-of-management-of-insomnia-in-patients-with-chronic-orofacial-pain
#19
REVIEW
G Almoznino, Y Haviv, Y Sharav, R Benoliel
In this review, we discuss the management of chronic orofacial pain (COFP) patients with insomnia. Diagnostic work-up and follow-up routines of COFP patients should include assessment of sleep problems. Management is based on a multidisciplinary approach, addressing the factors that modulate the pain experience as well as insomnia and including both non-pharmacological and pharmacological modalities. Parallel to treatment, patients should receive therapy for comorbid medical and psychiatric disorders, and possible substance abuse that may be that may trigger or worsen the COFP and/or their insomnia...
November 2017: Oral Diseases
https://www.readbyqxmd.com/read/27851868/pharmacotherapies-for-sleep-disturbances-in-dementia
#20
REVIEW
Jenny McCleery, Daniel A Cohen, Ann L Sharpley
BACKGROUND: Sleep disturbances, including reduced nocturnal sleep time, sleep fragmentation, nocturnal wandering, and daytime sleepiness are common clinical problems in dementia, and are associated with significant caregiver distress, increased healthcare costs, and institutionalisation. Drug treatment is often sought to alleviate these problems, but there is significant uncertainty about the efficacy and adverse effects of the various hypnotic drugs in this vulnerable population. OBJECTIVES: To assess the effects, including common adverse effects, of any drug treatment versus placebo for sleep disorders in people with dementia, through identification and analysis of all relevant randomised controlled trials (RCTs)...
November 16, 2016: Cochrane Database of Systematic Reviews
keyword
keyword
85081
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"